SG10201504801VA - Azaindazole compounds and methods of use - Google Patents
Azaindazole compounds and methods of useInfo
- Publication number
- SG10201504801VA SG10201504801VA SG10201504801VA SG10201504801VA SG10201504801VA SG 10201504801V A SG10201504801V A SG 10201504801VA SG 10201504801V A SG10201504801V A SG 10201504801VA SG 10201504801V A SG10201504801V A SG 10201504801VA SG 10201504801V A SG10201504801V A SG 10201504801VA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- azaindazole compounds
- azaindazole
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69352505P | 2005-06-22 | 2005-06-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201504801VA true SG10201504801VA (en) | 2015-07-30 |
Family
ID=37595833
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG201004298-4A SG162807A1 (en) | 2005-06-22 | 2006-06-22 | Azaindazole compounds and methods of use |
SG10201504801VA SG10201504801VA (en) | 2005-06-22 | 2006-06-22 | Azaindazole compounds and methods of use |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG201004298-4A SG162807A1 (en) | 2005-06-22 | 2006-06-22 | Azaindazole compounds and methods of use |
Country Status (27)
Country | Link |
---|---|
US (2) | US20070010523A1 (en) |
EP (1) | EP1906965B1 (en) |
JP (1) | JP5275794B2 (en) |
KR (2) | KR20140026644A (en) |
CN (1) | CN101242839B (en) |
AU (1) | AU2006262122B2 (en) |
BR (1) | BRPI0612112A8 (en) |
CA (1) | CA2612552C (en) |
DK (1) | DK1906965T3 (en) |
EA (1) | EA017278B9 (en) |
ES (1) | ES2543714T3 (en) |
HK (1) | HK1124241A1 (en) |
HR (1) | HRP20150832T1 (en) |
HU (1) | HUE025476T2 (en) |
IL (1) | IL188050A (en) |
MA (1) | MA29568B1 (en) |
MX (1) | MX2007015917A (en) |
NO (1) | NO340621B1 (en) |
NZ (1) | NZ564258A (en) |
PL (1) | PL1906965T3 (en) |
PT (1) | PT1906965E (en) |
RS (1) | RS54206B1 (en) |
SG (2) | SG162807A1 (en) |
SI (1) | SI1906965T1 (en) |
UA (1) | UA95777C2 (en) |
WO (2) | WO2007002667A2 (en) |
ZA (2) | ZA200800309B (en) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008520744A (en) | 2004-11-19 | 2008-06-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | Anti-inflammatory pyrazolopyrimidine |
EA017278B9 (en) | 2005-06-22 | 2013-01-30 | Кемосентрикс, Инк. | Azaindazole compounds and methods of use |
US7777035B2 (en) | 2005-06-22 | 2010-08-17 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
NZ571182A (en) | 2006-04-04 | 2010-09-30 | Univ California | Pyrazolo[3,4-d]pyrimidines |
US20090252779A1 (en) * | 2006-06-22 | 2009-10-08 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
EA015529B1 (en) | 2007-05-22 | 2011-08-30 | Кемосентрикс, Инк. | 3-(imidazolyl)pyrazolo[3,4-b]pyridines |
US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
NZ587051A (en) | 2008-01-04 | 2012-12-21 | Intellikine Llc | Isoquinolinone derivatives, compositions and methods of inhibiting phosphatidyl inositol-3 kinase (pi3 kinase) |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
WO2009134666A1 (en) | 2008-04-29 | 2009-11-05 | Boehringer Ingelheim International Gmbh | Indazole compounds as ccr1 receptor antagonists |
JP5411927B2 (en) | 2008-05-06 | 2014-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pyrazole compounds as CCR1 antagonists |
US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
BRPI0915231A2 (en) | 2008-07-08 | 2018-06-12 | Intellikine Inc | kinase inhibitor compounds and methods of use |
MX2011002636A (en) | 2008-09-11 | 2011-04-05 | Chemocentryx Inc | 4-amino-3-(imidazolyl)-pyrazolo[3,4-d]pyrimidines. |
UA103634C2 (en) | 2008-09-26 | 2013-11-11 | Берингер Ингельхайм Интернациональ Гмбх | Azaindazole compounds as ccr1 receptor antagonists |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
ES2570429T3 (en) | 2008-10-16 | 2016-05-18 | Univ California | Condensed Ring Heteroaryl Kinase Inhibitors |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
AU2009308687A1 (en) * | 2008-11-03 | 2010-05-06 | Chemocentryx, Inc. | Compounds for the treatment of osteoporosis and cancers |
US8362249B2 (en) * | 2009-04-27 | 2013-01-29 | Boehringer Ingelheim International Gmbh | CXCR3 receptor antagonists |
JP5807971B2 (en) * | 2009-04-27 | 2015-11-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | CXCR3 receptor antagonist |
CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
JP5640086B2 (en) * | 2009-08-03 | 2014-12-10 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニAziende Chimiche Riunite Angelini Francesco A.C.R.A.F.Societa Per Azioni | Process for producing 1-benzyl-3-hydroxymethyl-1H-indazole and derivatives thereof, and necessary magnesium intermediate |
WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
IN2012DN03449A (en) * | 2009-10-21 | 2015-10-23 | Boehringer Ingelheim Int | |
JP5542214B2 (en) | 2009-10-27 | 2014-07-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Heterocyclic compounds as CCR1 receptor antagonists |
GB201004311D0 (en) * | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
US8871786B2 (en) | 2010-04-30 | 2014-10-28 | Boehringer Ingelheim International Gmbh | Azaindazole amide compounds as CCR1 receptor antagonists |
ES2593256T3 (en) | 2010-05-21 | 2016-12-07 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulations |
WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
PL3181133T3 (en) | 2010-12-20 | 2019-12-31 | Pfizer Inc. | Novel fused pyridine compounds as casein kinase inhibitors |
EP2655371B1 (en) | 2010-12-23 | 2015-02-25 | Boehringer Ingelheim International GmbH | Pyrazolopiperidine compounds as ccr1 receptor antagonists |
CN103648499B (en) | 2011-01-10 | 2017-02-15 | 无限药品股份有限公司 | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
GB2488752A (en) * | 2011-02-21 | 2012-09-12 | Sony Dadc Austria Ag | Microfluidic Device |
US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
EP2734520B1 (en) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA2842190A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
WO2013032591A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
CA2846496C (en) | 2011-09-02 | 2020-07-14 | The Regents Of The University Of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
GB201115853D0 (en) * | 2011-09-14 | 2011-10-26 | Proximagen Ltd | New enzyme inhibitor compounds |
IN2014DN01883A (en) | 2011-09-14 | 2015-05-15 | Proximagen Ltd | |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
JP2015532287A (en) | 2012-09-26 | 2015-11-09 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | IRE1 regulation |
MX2015007051A (en) * | 2012-12-07 | 2016-01-12 | Chemocentryx Inc | Diazole lactams. |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
WO2015011099A1 (en) | 2013-07-22 | 2015-01-29 | Actelion Pharmaceuticals Ltd | 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives |
CA2925944C (en) | 2013-10-04 | 2023-01-10 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP4066834A1 (en) | 2014-03-19 | 2022-10-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN105801574A (en) * | 2014-12-31 | 2016-07-27 | 上海药谷药业有限公司 | Preparation method of 1H-pyrazolo[3,4-b]pyridine compound |
AR103399A1 (en) | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | DERIVATIVES OF (R) -2-METHYL-PIPERAZINE AS CXCR3 RECEIVER MODULATORS |
TR201900680T4 (en) | 2015-01-15 | 2019-02-21 | Idorsia Pharmaceuticals Ltd | Hydroxyalkyl-piperazine derivatives as CXCR3 Receptor modulators. |
CN108349985A (en) | 2015-09-14 | 2018-07-31 | 无限药品股份有限公司 | Solid form, preparation method, the composition and its application method comprising it of isoquinolines |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
WO2017176965A1 (en) * | 2016-04-07 | 2017-10-12 | Chemocentryx, Inc. | Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2017223422A1 (en) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Combination therapies |
CN108570049A (en) * | 2018-07-24 | 2018-09-25 | 上海毕得医药科技有限公司 | A kind of synthetic method of chloro- 1 hydrogen-pyrazolo [3,4-B] pyridines of 6- |
CN108794470B (en) * | 2018-07-25 | 2020-06-26 | 上海毕得医药科技有限公司 | 6-hydrazino-1H-pyrazolo [3,4-b ] pyridine and synthesis method of downstream product thereof |
CN110343103A (en) * | 2019-07-04 | 2019-10-18 | 深圳市格物致欣化学技术有限公司 | Pyrazolo-pyridines and preparation method thereof |
JP2022539830A (en) | 2019-07-10 | 2022-09-13 | ケモセントリックス,インコーポレイティド | Indane as a PD-L1 inhibitor |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0001647B1 (en) * | 1977-10-26 | 1982-11-03 | The Wellcome Foundation Limited | Imidazoline derivatives and salts thereof, their synthesis, pesticidal formulations containing the imidazolines, preparation thereof and their use as pesticides |
AU518569B2 (en) * | 1979-08-07 | 1981-10-08 | Farmos-Yhtyma Oy | 4-benzyl- and 4-benzoyl imidazole derivatives |
US4927942A (en) * | 1988-12-15 | 1990-05-22 | Texaco Chemical Co. | Method for the preparation of imidazoles |
JP5049447B2 (en) * | 2000-08-14 | 2012-10-17 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Substituted pyrazoles |
RU2286343C2 (en) * | 2001-08-10 | 2006-10-27 | Орто-Макнейл Фармасьютикал, Инк. | Substituted pyrazoles |
CZ2004519A3 (en) * | 2001-10-22 | 2004-12-15 | Pfizer Products Inc. | Piperazine derivatives exhibiting CCR1 receptor antagonist activity |
AU2003236500B9 (en) * | 2002-06-12 | 2009-07-02 | Chemocentryx, Inc. | 1-aryl-4-substituted piperazine derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders |
US7842693B2 (en) * | 2002-06-12 | 2010-11-30 | Chemocentryx, Inc. | Substituted piperazines |
US7589199B2 (en) * | 2002-06-12 | 2009-09-15 | Chemocentryx, Inc. | Substituted piperazines |
US20050256130A1 (en) * | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
US7435831B2 (en) | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
JP4845873B2 (en) | 2004-03-03 | 2011-12-28 | ケモセントリックス インコーポレーティッド | Bicyclic and bridged nitrogen heterocycles |
EA017278B9 (en) * | 2005-06-22 | 2013-01-30 | Кемосентрикс, Инк. | Azaindazole compounds and methods of use |
-
2006
- 2006-06-22 EA EA200800100A patent/EA017278B9/en not_active IP Right Cessation
- 2006-06-22 KR KR1020147002448A patent/KR20140026644A/en not_active Application Discontinuation
- 2006-06-22 WO PCT/US2006/024969 patent/WO2007002667A2/en active Application Filing
- 2006-06-22 JP JP2008518388A patent/JP5275794B2/en active Active
- 2006-06-22 UA UAA200800722A patent/UA95777C2/en unknown
- 2006-06-22 MX MX2007015917A patent/MX2007015917A/en active IP Right Grant
- 2006-06-22 SI SI200631957T patent/SI1906965T1/en unknown
- 2006-06-22 WO PCT/US2006/024313 patent/WO2007002293A2/en active Application Filing
- 2006-06-22 BR BRPI0612112A patent/BRPI0612112A8/en not_active Application Discontinuation
- 2006-06-22 US US11/474,130 patent/US20070010523A1/en not_active Abandoned
- 2006-06-22 SG SG201004298-4A patent/SG162807A1/en unknown
- 2006-06-22 ZA ZA200800309A patent/ZA200800309B/en unknown
- 2006-06-22 SG SG10201504801VA patent/SG10201504801VA/en unknown
- 2006-06-22 AU AU2006262122A patent/AU2006262122B2/en active Active
- 2006-06-22 NZ NZ564258A patent/NZ564258A/en not_active IP Right Cessation
- 2006-06-22 KR KR1020077031045A patent/KR101418024B1/en active IP Right Grant
- 2006-06-22 PT PT67737734T patent/PT1906965E/en unknown
- 2006-06-22 US US11/474,132 patent/US7524845B2/en active Active
- 2006-06-22 PL PL06773773T patent/PL1906965T3/en unknown
- 2006-06-22 DK DK06773773.4T patent/DK1906965T3/en active
- 2006-06-22 CA CA2612552A patent/CA2612552C/en active Active
- 2006-06-22 EP EP20060773773 patent/EP1906965B1/en active Active
- 2006-06-22 RS RS20150517A patent/RS54206B1/en unknown
- 2006-06-22 HU HUE06773773A patent/HUE025476T2/en unknown
- 2006-06-22 CN CN2006800304091A patent/CN101242839B/en active Active
- 2006-06-22 ES ES06773773.4T patent/ES2543714T3/en active Active
-
2007
- 2007-12-11 IL IL188050A patent/IL188050A/en active IP Right Grant
- 2007-12-26 MA MA30516A patent/MA29568B1/en unknown
-
2008
- 2008-01-21 NO NO20080408A patent/NO340621B1/en not_active IP Right Cessation
-
2009
- 2009-02-12 HK HK09101322.8A patent/HK1124241A1/en unknown
- 2009-03-16 ZA ZA2009/01845A patent/ZA200901845B/en unknown
-
2015
- 2015-08-04 HR HRP20150832TT patent/HRP20150832T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201504801VA (en) | Azaindazole compounds and methods of use | |
IL196956A0 (en) | Aza-benzofuranyl compounds and methods of use | |
IL176958A0 (en) | Compounds and methods of use | |
IL185914A0 (en) | Pyrimidine compounds and methods of use | |
ZA200709626B (en) | Multicyclic compounds and methods of their use | |
EP2023718A4 (en) | Creatine-ligand compounds and methods of use thereof | |
ZA200802501B (en) | Indenoisoquinolinone analogs and methods of use thereof | |
EP1942815A4 (en) | Medical installation tool and methods of use | |
IL197060A0 (en) | Aza-benzothiophenyl compounds and methods of use | |
IL186970A0 (en) | Thiazole compounds and methods of use | |
IL188078A0 (en) | Nano-ionic liquids and methods of use | |
IL194028A0 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
IL185309A0 (en) | Isoqunoline compounds and methods of use thereof | |
IL193693A0 (en) | Purine compounds and methods of use thereof | |
IL186342A0 (en) | Spirocyclic heterocycic derivaives and methods of their use | |
HK1135099A1 (en) | Aza-indolyl compounds and methods of use | |
EP1812451A4 (en) | Compounds and methods of use thereof | |
EP1850848A4 (en) | Tetracyclic sulfonamide compounds and methods of use thereof | |
HK1161122A1 (en) | Use of 24-norudca 24-norudca | |
IL190583A0 (en) | Pth formulations and methods of use | |
ZA200900896B (en) | Aza-benzofuranyl compounds and methods of use | |
EP1931370A4 (en) | Use of des-aspartate-angiotensin i | |
EP1978999A4 (en) | Isolated mcpip and methods of use | |
ZA200901009B (en) | Aza-benzothiophenyl compounds and methods of use | |
ZA200807956B (en) | Purine compounds and methods of use thereof |